TABLE 1.
Clinical features of patients requiring treatment for immune thrombotic thrombocytopenic purpura in relation to COVID‐19 vaccination status
| Clinical features | Frequency |
|---|---|
| Type of TTP presentation | De novo 59 (66%) |
| Clinical relapse 7 (8%) | |
| ADAMTS13 relapse 24 (27%) | |
| Timing of TTP presentation in relation to COVID‐19 vaccination | Unvaccinated 19 (21%) |
| Before receiving vaccination 7 (8%) | |
| After receiving vaccination 58 (64%) | |
| Unknown 6 (7%) | |
| Type of vaccine used | ChAdOx1 nCov‐19 (Oxford/AstraZeneca) 27 (47%) |
| BNT162b2 (Pfizer) 30 (52%) | |
| Unknown 1 (2%) | |
| Total number of doses received per patienta | No doses 19 |
| One dose 12 | |
| Two doses 47 | |
| Three doses 4 | |
| Unknown 8 |
TTP, thrombotic thrombocytopenia purpura.
a
Includes doses received before and after episode of treatment for TTP.